Boehringer Ingelheim GmbH

99 articles with Boehringer Ingelheim GmbH

• Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

  5/29/2019

  Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.

• Boehringer Ingelheim and Optimum Patient Care Launch First US Primary Care Patient Registry to Improve COPD Care

  5/21/2019

  First-of-its-kind registry to exclusively focus on chronic obstructive pulmonary disease (COPD) treatment by primary care physicians

• Boehringer Ingelheim announces resolution of Cyltezo® patent litigation

  5/14/2019

  Boehringer Ingelheim announced the resolution of all intellectual property-related litigation with AbbVie concerning Cyltezo® (adalimumab-adbm) and the reference medicine Humira® (adalimumab).

• AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

  5/14/2019

  AbbVie announced that it has resolved U.S. HUMIRA litigation with Boehringer Ingelheim.

• Financial year 2018: Boehringer Ingelheim grows and invests

  4/17/2019

  Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases

• PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform

  4/17/2019

  PureTech Health to receive up to $26 million in upfront payments, research support, and preclinical milestones and is eligible to potentially receive more than $200 million in milestones, in addition to royalties

• Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine

  4/9/2019

  The partnership of Boehringer Ingelheim and GST proves its commitment to bring highly innovative therapeutics for horses to customers

• Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

  3/29/2019

  New molecular platform to access intracellular targets across a broad range of tumor cell types

• Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

  3/18/2019

  Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease

• Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development

  2/26/2019

  Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test.

• Bioharmony Therapeutics and Boehringer Ingelheim Collaborate to Advance Bacteriophage Lysin Therapeutics for the Treatment of Multi-Drug Resistant Bacterial Infections

  1/15/2019

  Collaboration aims to develop first-in-class therapies for treatment resistant hospital acquired bacterial infections caused by Acinetobacter baumannii Infectious diseases are an area of interest of Boehringer Ingelheim’s Research Beyond Borders (RBB) department, which explores emerging science and technology beyond the company’s core areas of focus

• Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Therapies

  1/3/2019

  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide

• Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies

  1/3/2019

  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide

• Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

  12/13/2018

  The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S.

• DOMAIN THERAPEUTICS SIGNS A MULTI-TARGET RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH BOEHRINGER INGELHEIM

  12/4/2018

  Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases

• AGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in Spain

  12/4/2018

  - Acquisition Will Give AGC Foothold in Europe and Broaden Its Pharma CDMO Business -

• Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

  11/15/2018

  Boehringer Ingelheim Expands Biomarker-driven Oncology Programs

• EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 million (USD 245 million) Transaction

  9/14/2018

  ViraTherapeutics sale marks third exit from EMBL Ventures’ current fund ETF II Heidelberg, Germany, 13th Sept

• Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

  9/13/2018

  Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics

• Boehringer Ingelheim To Donate 75,000 Doses Of Rabies Vaccine To The Global Alliance For Rabies Control Through Shots For Good Initiative

  9/12/2018

  In recognition of World Rabies Day on September 28, this significant rabies vaccine donation will support GARC's efforts to address deaths due to rabies in Madagascar.